JCAR015 Faces Major Impediment, Juno Therapeutics Shares Fall Fast
Posted on 11/28/2016
Finding a cure for cancer is not easy. Seattle-based Juno Therapeutics, a biopharmaceutical company, witnessed a precipitous drop in its stock price after another hold has been placed on its Phase II clinical trial in regards to anti-cancer therapies. This is in regard to the JCAR015 program, also known as the “ROCKET” trial. Juno Therapeutics […]
